Cargando…
Tumor Mouse Model Confirms MAGE-A3 Cancer Immunotherapeutic As an Efficient Inducer of Long-Lasting Anti-Tumoral Responses
PURPOSE: MAGE-A3 is a potential target for immunotherapy due to its tumor-specific nature and expression in several tumor types. Clinical data on MAGE-A3 immunotherapy have raised many questions that can only be addressed by using animal models. In the present study, different aspects of the murine...
Autores principales: | Gérard, Catherine, Baudson, Nathalie, Ory, Thierry, Louahed, Jamila |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4022504/ https://www.ncbi.nlm.nih.gov/pubmed/24830315 http://dx.doi.org/10.1371/journal.pone.0094883 |
Ejemplares similares
-
A Comprehensive Preclinical Model Evaluating the Recombinant PRAME Antigen Combined With the AS15 Immunostimulant to Fight Against PRAME-expressing Tumors
por: Gérard, Catherine, et al.
Publicado: (2015) -
P25. Access to diagnostics: a bottleneck for immunotherapeutics development - case example of MAGE-A3 cancer immunotherapeutic
por: Lykopoulos, K, et al.
Publicado: (2014) -
Association of homogeneous inflamed gene signature with a better outcome in patients with metastatic melanoma treated with MAGE-A3 immunotherapeutic
por: Baurain, Jean-François, et al.
Publicado: (2018) -
Safety and immunogenicity of MAGE-A3 cancer immunotherapeutic with dacarbazine in patients with MAGE-A3-positive metastatic cutaneous melanoma: an open phase I/II study with a first assessment of a predictive gene signature
por: Grob, Jean-Jacques, et al.
Publicado: (2017) -
NKT Cells as an Ideal Anti-Tumor Immunotherapeutic
por: Fujii, Shin-ichiro, et al.
Publicado: (2013)